J W UHR
Overview
Explore the profile of J W UHR including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
290
Citations
4639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ghetie M, Podar E, Ilgen A, Gordon B, UHR J, Vitetta E
Proc Natl Acad Sci U S A
. 1997 Jul;
94(14):7509-14.
PMID: 9207122
Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we...
12.
Vitetta E, Tucker T, Racila E, Huang Y, Marches R, Lane N, et al.
Blood
. 1997 Jun;
89(12):4425-36.
PMID: 9192767
The majority of BALB/c mice immunized with the BCL1 lymphoma-derived idiotype (Id+) IgM and subsequently challenged with BCL1 tumor cells develop a state of tumor dormancy. The vast majority of...
13.
Senderowicz A, Vitetta E, Headlee D, Ghetie V, UHR J, Figg W, et al.
Ann Intern Med
. 1997 Jun;
126(11):882-5.
PMID: 9163289
No abstract available.
14.
UHR J, Scheuermann R, Street N, Vitetta E
Nat Med
. 1997 May;
3(5):505-9.
PMID: 9142117
No abstract available.
15.
Baluna R, Sausville E, Stone M, Stetler-Stevenson M, UHR J, Vitetta E
Clin Cancer Res
. 1996 Oct;
2(10):1705-12.
PMID: 9816120
The major dose-limiting adverse effect of ricin A chain-containing immunotoxin (IT) therapy is vascular leak syndrome (VLS). Since plasma fibronectin (Fn) plays a role in maintaining microcirculatory integrity and since...
16.
Ghetie M, Podar E, Gordon B, Pantazis P, UHR J, Vitetta E
Int J Cancer
. 1996 Sep;
68(1):93-6.
PMID: 8895546
We describe the use of an immunotoxin (IT) cocktail (anti-CD22- and anti-CD19-ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi...
17.
Stone M, Sausville E, Fay J, Headlee D, Collins R, Figg W, et al.
Blood
. 1996 Aug;
88(4):1188-97.
PMID: 8695836
IgG-HD37-SMPT-dgA is a deglycosylated ricin A chain (dgA)-containing immunotoxin (IT) prepared by conjugating the monoclonal murine (MoAb) anti-CD19 antibody, HD37, to dgA using the heterobifunctional hindered disulfide linker, N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyldithio) toluene...
18.
Racila E, Hsueh R, Marches R, Tucker T, Krammer P, Scheuermann R, et al.
Proc Natl Acad Sci U S A
. 1996 Mar;
93(5):2165-8.
PMID: 8700902
Signal transduction initiated by crosslinking of antigen-specific receptors on T- and B-lymphoma cells induces apoptosis. In T-lymphoma cells, such crosslinking results in upregulation of the APO-1 ligand, which then interacts...
19.
UHR J, Marches R, Racila E, Tucker T, Hsueh R, Street N, et al.
Adv Exp Med Biol
. 1996 Jan;
406:69-74.
PMID: 8910672
No abstract available.
20.